Keros Therapeutics, Inc. Common Stock (KROS)
Keros Therapeutics, Inc. (KROS) is a biotechnology company focused on the development of novel therapeutics aimed at addressing hematologic and neurodegenerative disorders. The company specializes in targeting cytokine pathways to develop treatments that modulate hematopoiesis and neurobiology, with an emphasis on improving patient outcomes through innovative drug discovery and development.
Company News
Over 25 pharmaceutical companies are developing TGF-β inhibitor drugs targeting oncology and fibrosis treatments, with promising pipeline therapies showing potential for addressing significant unmet medical needs.
Harley-Davidson is exploring strategic alternatives for its financing unit, while Capri Holdings is selling Versace to Prada for $1.375 billion. Several other companies, including Impresoft, Keros Therapeutics, and Rivalry Corp., are also exploring strategic alternatives.
Stay updated on Wall Street news with our daily podcast available on Seeking Alpha, iTunes, and Spotify.
Keros Therapeutics, Inc. (KROS) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
The company appointed a new director and an analyst reiterated his position on the stock.